Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corona RemediesNSE:CORONA +0.37%18 Interest Coverage is 37.49 as of Mar. 2026, which is 6% above its 10-year median of 35.32. GuruFocus rates NSE:CORONA with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 687 Drug Manufacturers companies, Corona Remedies ranks better than 69.58% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Corona Remedies's
Operating Income
for the
three
months ended in Mar. 2026 was ₹517 Mil. Corona Remedies's Interest Expense for the
three
months ended in Mar. 2026 was ₹-14 Mil.
Corona Remedies's interest coverage for the quarter that ended in Mar. 2026 was 37.49.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Corona Remedies's Interest Coverage or its related term are showing as below:
NSE:CORONA'
s Interest Coverage Range Over the Past 10 Years
Min: 11.12 Med: 35.32 Max: 56.08
Current: 42.1
NSE:CORONA's Interest Coverage is ranked better than 69.58% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.7
vs NSE:CORONA: 42.10
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Corona Remedies Interest Coverage Related Terms
Corona Remedies Interest Coverage Historical Data
* Premium members only.
The historical data trend for Corona Remedies's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:CORONA vs LLY, JNJ, ABBV: Interest Coverage Comparison
For the Drug Manufacturers - General subindustry, Corona Remedies's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corona Remedies Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Corona Remedies's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Corona Remedies's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corona Remedies (NSE:CORONA) has a Interest Coverage of 37.49 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Corona Remedies and its competitors. This is near median its historical median of 35.32. Over the past decade, Corona Remedies' Interest Coverage has ranged from 11.12 to 56.08. According to the industry distribution chart, Corona Remedies ranks #209 out of 687 companies in the Drug Manufacturers industry, placing it in the top 30.4%.
Is Corona Remedies' Interest Coverage too high?
Corona Remedies' current Interest Coverage of 37.49 is near median its 10-year median of 35.32. Over the past 10 years, this metric has ranged from a low of 11.12 to a high of 56.08. The Drug Manufacturers industry median Interest Coverage is 12.70. Corona Remedies' value of 37.49 is 195.2% above this industry median. Based on the distribution chart, Corona Remedies ranks #209 out of 687 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Corona Remedies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Corona Remedies' Interest Coverage compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Corona Remedies ranks #209 out of 687 companies for Interest Coverage. This puts Corona Remedies in the upper half of its industry. The industry median Interest Coverage is 12.70. Corona Remedies' value of 37.49 is 195.2% above this benchmark. Historically, Corona Remedies' own Interest Coverage has ranged from 11.12 to 56.08 over the past decade. While the company's 10-year median is 35.32 vs. the industry median of 12.70, Corona Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.70, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corona Remedies's current Interest Coverage of 37.49 is 195.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Corona Remedies and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corona Remedies's current Interest Coverage is 37.49, which is near median its own 10-year median of 35.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corona Remedies stock overvalued right now?
Corona Remedies (NSE:CORONA) has a current Interest Coverage of 37.49. The current Interest Coverage is 37.49, which is near median its 10-year median of 35.32 and 195.2% above the Drug Manufacturers industry median of 12.70. Corona Remedies' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Corona Remedies (NSE:CORONA), the current Interest Coverage is 37.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
18GF Score
Get the complete analysis for NSE:CORONA
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CORONA has been successfully added to your 
